The official letter 5748/QLD-ĐK Updating pharmacology information of fluoroquinolone antibacterial drugs

517
The official letter 5748/QLD-ĐK
The official letter 5748/QLD-ĐK
The official letter 5748/QLD-ĐK Updating pharmacology information of fluoroquinolone antibacterial drugs
5 (100%) 9 votes

The official letter 5748/QLD-ĐK Updating pharmacology information of fluoroquinolone antibacterial drugs

THE MINISTRY OF HEALTH

DRUG ADMINISTRATION
——–

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness
—————
No. 5748/QLD-ĐK

Ref. Updating pharmacology information of fluoroquinolone antibacterial drugs

Hanoi , April 27th 2017

Respectfully to:

– Departments of Health of central-affiliated cities and provinces.

– Hospitals, medical facilities with beds under the ministry of Health

– Registering company have drugs circulating in Vietnam

On July 26th 2016, The US FDA approved changes to the labels and package inserts of fluoroquinolone antibacterial drugs for systemic use in order to minimize the risk of severe disabling and potentially permanent adverse drug reactions of the tendons, muscles, joints, peripheral nerves and central nervous system when using these drugs on patient with sinusitis, bronchitis and uncomplicated urinary tract infection. In Vietnam, fluoroquinolone antibacterial drugs which are granted visa numbers contain these following substances: ciprofloxacin, levofloxacin, ofloxacin, norfloxacin, pefloxacin, moxifloxacin and lomefloxacin.

Following letter number 24812/QLD-TT dated December 21st 2016 of drug administration of Vietnam on providing information for medical staffs about safety, effectiveness of fluoroquinolone antibacterial drugs and based on the conclusions of advisory council for granting drug visa numbers – Ministry of Health, in order to ensure rational, safe and effective use of medicines, Drug of administration of Vietnam requires:


  • Fluoroquinolones are related to severe disabling and unrecoverable adverse reactions in different organ systems of the body. These reactions can appear at the same time in a patient. These recognized adverse reactions include tendinitis, tendon rupture, joint pain, muscle pain, peripheral neuropathy and adverse reactions in central nervous system (hallucinations, anxiety, depression, insomnia, bad headache and confusion). These reactions can appear within some hours or some weeks after drug administration. The above reactions can be seen in patients at any age or without existent risk factors.
  • Discontinue right after any signs or symptoms of adverse reactions appear. Moreover, avoid using fluoroquinolone antibacterial drugs in patients who experienced adverse reactions related to fluoroquinolones.

The official letter 5748/QLD-ĐK Updating pharmacology information of fluoroquinolone antibacterial drugs

DOWNLOAD FULL ENGLISH VERSION HERE

5748_QLD_ĐK_EN

COPY PLEASE REFER TO VNRAS.COM

1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here